Sweden's centre-right government and its far-right ally have announced they will invest around €6.5 million in 2025 to shorten queues and increase the capacity of Swedish hospitals and health care ...

The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...

The nonaddictive painkiller suzetrigine (Journavx) is as effective for acute pain as a common opioid treatment ...

On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...

Patients seeking an opioid-free way to handle pain experienced in the short-term will soon have a new option.

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side effects.

By Liam Stack Newsday plans to sue Bruce Blakeman, the executive of Nassau County, N.Y., after he made The New York Post the government’s official publication. By Santul Nerkar Senior ...

The FDA has approved Journavx, an oral medication for treating pain that doesn't target the brain like addictive opioids.

The U.S. Food and Drug Administration (FDA) approved Journavx (suzetrigine) oral tablets on Thursday as a first-in-class non-opioid analgesic to treat acute pain in adults. “Today’s approval is an ...

A weekly collection of lesson plans, writing prompts and activities from The Learning Network, a site that helps educators and students teach and learn with The New York Times.

White House press secretary Karoline Leavitt announced that tariffs on Canada and Mexico will begin on February 1, as decided earlier dismissing reports that claimed the tariffs will be deferred ...